Adriamycin alone or in combination in 100 patients with carcinoma of the cervix or vagina.
One hundred consecutive evaluable patients with advanced carcinoma of the cervix or vagina were treated with doxorubicin (Adriamycin) alone or in combination. The use of Adriamycin in conjunction with cyclophosphamide and 5-fluorouracil resulted in the highest response rate with all responders continuing to respond.
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014625:Vaginal Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate